Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: A multicenter phase II study of the Greek Cooperative Group for Lung Cancer

Lung Cancer

Volumn 21, Issue 3, 1998, Pages 213-220

  Georgoulias, Vassilis ^a   Androulakis, Nikos ^a   Bouros, Demosthenis ^b   Kouroussis, Charalampos ^a   Chatzakis, Kostas ^b   Papadakis, Manolis ^c   Apostopoloulou, Fotini ^d   Georgopoulou, Theoni ^c   Kotsakis, Thanos ^a   Souklakos, John ^a   Hatzidaki, Dora ^a   Vlachonikolis, John ^b   Panagos, Gerassimos ^e  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

^e Oncology Department   (Greece)

Author keywords

Chemotherapy; Cisplatin; Docetaxel; NSCLC; Vinorelbine

Indexed keywords

CISPLATIN; DOCETAXEL; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ABSCESS; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT COMPLIANCE; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0032170938     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00028-2     Document Type: Article

References (23)

1. Ginsberg RJ, Vokes EE, Raben A. Non-small cell lung cancer. In: Devita VT Jr, Hellman S, Rosenberg SA, editors. Cancer Principles and Practice of Oncology, 5th ed. Philadelphia: Lippincott-Raven, 1997:858-911.
2. Francis A.P., Rigas J.R., Kris M.G., Pisters K.M.W., Orazem J.P., Wooley K.J., Heelan R.T. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol. 12:1994;1232-1237.
3. Fossela F.V., Lee J.S., Murphy W.K.et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 12:1994;1238-1244.
4. Kunitoh H., Watanabe K., Onoshie T., Furuse K., Nitani M., Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer. A Japanese cooperative study. J Clin Oncol. 14:1996;1649-1655.
5. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 75:1995;968-972.
6. Gueritte-Voegelein F., Guenard D., Lavella F., Le Goff M.T., Mangatal L., Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem. 34:1991;992-998.
7. Ringel I., Horwitz S.B. Studies with PR56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 83:1991;288-291.
8. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalplhin J.C. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol. 14:1991;115-119.
9. Furuse K., Kubota K., Kawahara M.et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid for previously untreated advanced non-small cell lung cancer. Lung Cancer. 11:1994;385-391.
10. Clerici M., Bratti S., Celano A.et al. Non-small cell lung cancer treatment with vinorelbine monotherapy: a phase II study. Anticancer Res. 15:1995;477-478.
11. Veronesi A., Frivellari D., Magri M.D.et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer. 32A:1996;1809-1811.
12. Le Chevalier T., Brisgand D., Douillard J.Y.et al. Randomizing study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
13. Zavala F., Guenard D., Potier P. Interaction of vinblastine analogues with tubulin. Separatium Experiential. 34:1978;1497-1498.
14. Berille J., Le Chevalier T., Zalcberg J.R.et al. Overview on taxotere-cisplatin (TXT-CDDP) combination in non-small-cell lung cancer (NSCLC). Ann Oncol. 7(Suppl 5):1996;50.
15. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. Ann Oncol 1998;9:331-4.
16. Wozniak A.J., Kromlay J.J., Balcerzak S.P.et al. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group Study (SWOG-9308). Proc Am Soc Clin Oncol. 15:1996;374.
17. Scagliotti G.V., Dellarinis F., Rimmoldi R.et al. Schedule modification of vinorelbine in the combination with cisplatin as a consequence of severe toxicity in advanced non-small-cell lung cancer. Lung Cancer. 11(Suppl 1):1994;124.
18. Kourousis Ch., Kakolyris S., Androulakis N.et al. First-line treatment of non-small cell lung carcinoma with docetaxel and vinorelbine: a phase II study. Proc Am Soc Clin Oncol. 15:1996;405.
19. Miller A.B., Hoogstaten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47:1981;207-214.
20. Kaplan E.L., Meir P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 53:1985;457-481.
21. Van Oosterom A.T., Schrijvers D. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part II: clinical experience. Anti-Cancer Drugs. 6:1995;356-368.
22. Hohneker J.A. A summary of vinorelbine (Navelbine) safety data from North American Clinical Trial. Semin Oncol. 21(Suppl 5):1994;42-47.
23. Viallet J., Laberge F., Martins H.et al. A phase II trial of docetaxel alternating with cisplatin and vinorelbine in non-small cell lung cancer. Ann Oncol. 7(Suppl 5):1996;93.